SCHEMBL6324735

SCHEMBL6324735

Cc1ccc(-c2noc(N)c2C(=O)NCc2cccs2)o1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
POLB P06746 1/20 0.51
RAB9A P51151 8/20 0.49
NPC1 O15118 7/20 0.49
HPGD P15428 5/20 0.48
MAPT P10636 3/20 0.48
TP53 P04637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 3/20 0.47
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317800 0.84 GAA (0.53) ALDH1A1CYP1A2CYP2D6CYP2C19HPGD
SCHEMBL6314998 0.83 MAPT (0.44) ALDH1A1POLBMAPTHSD17B10TSHR
SCHEMBL6315542 0.83 ADORA2A (0.51) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6321162 0.82 HPGD (0.47) ALDH1A1HPGDLMNAKDM4EHTT
SCHEMBL6315025 0.82 ALDH1A1 (0.53) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6322602 0.81 KMT2A (0.49) ALDH1A1POLBHPGDMAPTMEN1
SCHEMBL6315807 0.81 TSHR (0.57) ALDH1A1POLBRAB9ANPC1HPGD
SCHEMBL6319034 0.80 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6316546 0.80 ALDH1A1 (0.55) ALDH1A1NPC1KMT2A
SCHEMBL6314500 0.80 ALDH1A1 (0.48) ALDH1A1CYP1A2CYP2D6CYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALDH1A1 4444/4885CYP1A2 4402/4885CYP2D6 4669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.